Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
1469.6(c) 1480(c) 1479.2(c) 1482.2(c) 1467.6 Last
27 499 190 25 667 001 22 006 436 6 756 961 311 092 Volume
+2.24% +0.71% -0.05% +0.20% -0.99% Change
More quotes
Financials (GBP)
Sales 2018 30 561 M
EBIT 2018 8 411 M
Net income 2018 3 913 M
Debt 2018 22 059 M
Yield 2018 5,39%
Sales 2019 31 391 M
EBIT 2019 8 475 M
Net income 2019 4 431 M
Debt 2019 22 289 M
Yield 2019 5,40%
P/E ratio 2018 20,83
P/E ratio 2019 16,44
EV / Sales2018 3,13x
EV / Sales2019 3,05x
Capitalization 73 535 M
More Financials
Company
GlaxoSmithkline is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (57.2%): intended for respiratory diseases (40.5% of net sales), HIV infection (25.2%), immune system disorders (2.2%) ) and other (32.1%); - OTC and... 
Sector
Pharmaceuticals
Calendar
02/06Earnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
12/13Vectura Loses U.K. Court Case Against GSK Over Patents
DJ
12/11NeuroMetrix Agrees with GlaxoSmithKline on 2019 Quell Joint Development Progr..
DJ
12/11Shares join global stock recovery but Brexit nerves weigh
RE
12/11ASTRAZENECA : U.K. pharmas shrug off Brexit vote delay
AQ
12/10EUROPE MARKETS: European Stocks End Sharply Lower As Data Add To Worries Abou..
DJ
12/10LONDON MARKETS: FTSE 100 Dragged Lower As U.K.'s May Delays Brexit Vote
DJ
12/06Unilever CMO Keith Weed to Retire -- 2nd Update
DJ
12/06Collapse of Tesco re-trial casts cloud over British fraud agency
RE
12/06Euro Health Stocks No Longer Insulated From Global Selloff -- Market Talk
DJ
12/05Unilever Boosts health drink footprint with Horlicks buy for Rs 27,750 cr
AQ
More news
Analyst Recommendations on GLAXOSMITHKLINE
More recommendations
Sector news : Pharmaceuticals - NEC
08:55aBAYER : Thyssenkrupp proposes former Bayer finance chief as CFO
RE
08:55aTHYSSENKRUPP : to Appoint Johannes Dietsch as CFO
DJ
08:48aJOHNSON & JOHNSON : J&J Pulled Into Court Fight
DJ
08:15aSHIRE : Rule 2.9 Announcement
DJ
12/13JOHNSON & JOHNSON : Drafted Into Fight Over Shareholder Lawsuits
DJ
More sector news : Pharmaceuticals - NEC
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 16,2  GBP
Spread / Average Target 9,2%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE12.08%92 739
JOHNSON & JOHNSON5.81%394 519
PFIZER23.05%256 128
NOVARTIS6.84%226 072
ROCHE HOLDING LTD.3.96%222 010
MERCK AND COMPANY40.41%202 855